Newly diagnosed with metastatic prostate cancer without small-cell histologic features (may have received prior surgery or radiation therapy for local disease or palliative therapy);
Less than 3 months of androgen deprivation therapy for metastatic disease (may have received prior adjuvant/neoadjuvant hormone therapy);
Eligible for abiraterone therapy
BC Cancer Agency
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
BC Cancer Agency has requested a voluntary withdrawal of the pCODR 10166 Abiraterone (Zytiga) for PC Submission. As per pCODR Procedures B18.104.22.168 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue the review as a PAG Submission.
‡ Patient Advocacy Groups (or individual patients and caregivers
when there is no patient group) and Clinicians who are registered
with pCODR are eligible to provide Input and Feedback.
Deadlines for Input and Feedback are by the end of the pCODR business day
(5P.M. Eastern Time) of the date noted.